People · Operator
Named in public records as an officer, director or promoter · active 2010–2022 · Other, Biotechnology, Pharmaceuticals, Retailing
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Direct Vet Marketing, Inc. | — | Other | Series D+ | $292.6M | $3.9B | 2010 |
| Compass Therapeutics LLC | — | Biotechnology | Series D+ | $132.6M | $900.7M | 2015 |
| Ankyra Therapeutics, Inc. | — | Biotechnology | Series C | $59.5M | $1.2B | 2021 |
| Avitide, Inc. | — | Pharmaceuticals | Series A | $40.9M | $309.7M | 2013 |
| Amagma, Inc. | — | Biotechnology | Series B | $28.6M | $138.7M | 2022 |
| Fetch Enterprises Inc | — | Retailing | Pre-Seed | $934K | $7.3M | 2010 |
Philip Ferneau at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Philip Ferneau on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Tillman Gerngross | 3 | 5 |
| Ajay Royan | 2 | 13 |
| DAVID SHAW | 2 | 12 |
| Errik Anderson | 2 | 8 |
| Philip J. Ferneau | 2 | 6 |
| Jonathan Sheller | 2 | 2 |
| Carl Gordon | 1 | 24 |
| Michael Ross | 1 | 18 |
| Kevin Bitterman | 1 | 15 |
| Rishi Gupta | 1 | 12 |
| Amy Schulman | 1 | 11 |
| Ben Auspitz | 1 | 9 |
| Terrance McGuire | 1 | 9 |
| Stephen Squinto | 1 | 8 |
| Ian Ratcliffe | 1 | 6 |
| DAVID E. SHAW | 1 | 5 |
| Tillman U. Gerngross | 1 | 5 |
| Claudio Nessi | 1 | 5 |
| Todd Warden | 1 | 5 |
| Edward McNamara | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.